Should I Take AREDS2 Eye Vitamins for Drusen or AMD?

Should I take AREDS2 if I have drusen but not macular degeneration?

Not automatically. Drusen are part of how an eye clinician classifies AMD risk, but the National Eye Institute separates early AMD from intermediate AMD based on the number and size of drusen.

The practical distinction is this: early AMD includes many small drusen or a few medium drusen, while intermediate AMD includes many medium drusen or one or more large drusen, according to the National Eye Institute's AREDS/AREDS2 clinical-trials overview. Advanced AMD involves geographic atrophy or abnormal blood vessels affecting the central retina. A label cannot make that call. Your retinal exam does.

The National Eye Institute's AREDS/AREDS2 FAQ states that the formulas benefited people with intermediate or late AMD, with no benefit for people with early AMD or people without AMD. That is the decision point. Do not translate “I have drusen” into “I need AREDS2” without confirming which stage your clinician documented.

Use the diagnosis, not the anxiety. At an eye appointment, ask: “Is my AMD early, intermediate, or advanced, and does that make me a candidate for the AREDS2 formula?” That one question cuts through most label confusion.

Can AREDS2 prevent macular degeneration from starting?

No. AREDS2 cannot prevent macular degeneration from starting; the National Eye Institute says the supplements may delay progression from intermediate to advanced AMD.

This is the cleanest way to set expectations. AREDS2 is not a general eye-health insurance policy, and it is not a cure. It is a targeted formula studied in people already at elevated risk of progression.

In the original AREDS research summarized by the National Eye Institute, the formulation reduced progression from intermediate to advanced AMD by 25% and central vision loss by 19% versus placebo among high-risk participants. The same NEI summary reports that, at 10-year follow-up, 34% of high-risk participants originally assigned to AREDS progressed to advanced AMD compared with 44% originally assigned to placebo.

Those results explain why clinicians may discuss AREDS2 when intermediate disease is present. They do not turn the supplement into a substitute for monitoring. Keep scheduled eye care, and seek urgent evaluation for new vision changes rather than waiting to see whether a supplement changes them.

Who benefits from AREDS2 vitamins?

People with intermediate AMD in one or both eyes, or intermediate AMD in one eye and advanced AMD in the other, are the groups most closely matched to the evidence.

The 2013 JAMA AREDS2 randomized clinical trial enrolled 4,203 adults aged 50 to 85 with bilateral large drusen or large drusen in one eye and advanced AMD in the other. It did not enroll people without AMD or those with early AMD because earlier AREDS results had shown no benefit for those groups.

That enrollment rule matters. A supplement claim can sound broad, but the evidence is narrow by design. The useful question is not “Is AREDS2 good for eyes?” It is “Do my eyes match the patients studied?”

Compare options by job, not by marketing. A standard multivitamin is a broad nutrient product. Standalone lutein and zeaxanthin are individual ingredients. Food-first eating is a nutrition pattern. AREDS2 is a specific high-dose combination studied for a defined AMD-risk group. They are not interchangeable.

Why does AREDS2 contain zinc and copper?

AREDS2 contains zinc and copper because zinc was part of the studied formula and copper was included to address zinc-related copper deficiency risk.

The National Eye Institute's FAQ lists the AREDS2 formula as vitamin C 500 mg, vitamin E 400 IU, zinc 80 mg, copper 2 mg, lutein 10 mg, and zeaxanthin 2 mg. Copper is not decorative label clutter. NEI explains that high zinc intake can cause copper-deficiency anemia and reports no evidence that the formula's copper amount was harmful in the trials.

The NIH Office of Dietary Supplements copper fact sheet explains the mechanism: high zinc intake can interfere with copper absorption, and excessive zinc supplement use can lead to copper deficiency. It also sets the adult tolerable upper intake level for zinc at 40 mg per day because of copper-related risks. That makes duplicate zinc products a clinician-review issue, not a minor technicality.

Beta-carotene was removed from AREDS2 and replaced with lutein and zeaxanthin. In the 2013 JAMA trial, lung cancers occurred in 23 participants assigned to beta-carotene and 11 participants assigned to no beta-carotene; cases were mostly among former smokers. The trial concluded that lutein and zeaxanthin were an appropriate carotenoid substitute because of beta-carotene's potential lung-cancer risk in former smokers.

Build a better clinician conversation

Bring the full picture. The fastest way to get a useful answer is to reduce the clinician's cognitive load before the appointment ends.

1. Bring every label. Include a daily multivitamin, eye formula, zinc product, vitamin E product, and any herbal or nutrition supplement.
2. State smoking history plainly. Ask: “Does my current or former smoking history change which carotenoid formula is appropriate?”
3. Name prescription medicines. The NIH Office of Dietary Supplements vitamin E fact sheet says vitamin E can interact with anticoagulant and antiplatelet medicines, and advises people who take medicines regularly to discuss vitamin E intake with their health care providers.
4. Ask for the diagnosis in writing. Use: “Please tell me whether this is early, intermediate, or advanced AMD, and whether the AREDS2 evidence applies to me.”
5. Report side effects and vision changes. Use: “Here is what changed, when it changed, and every product I take.” Specific inputs produce a safer review.

The goal is not to collect the most supplements. The goal is to match the formula, if any, to the diagnosis and avoid creating overlap that nobody has reviewed.